Brief debrisoquin administration to assess central dopaminergic function in children |
| |
| Authors: | M A Riddle B A Shaywitz J F Leckman G M Anderson S E Shaywitz M T Hardin S I Ort D J Cohen |
| |
| Affiliation: | 1. The Child Study Center, Yale University School of Medicine, New Haven, CT 06510, USA;2. the Children''s Clinical Research Center, Yale University School of Medicine, New Haven, CT 06510, USA;3. the Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA;4. the Department of Pediatrics, Yale University School of Medicine, New Haven, CT 06510, USA;5. the Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510, USA;6. the Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA;1. Department of Psychology, Université du Québec à Montréal, C.P. 8888, Montreal, QC, Canada, H3C 3P8;2. CHU Sainte-Justine Research Center, Montreal, QC, Canada;3. Department of Psychiatry, Université de Montréal, Montreal, QC, Canada;4. Centre Hospitalier de l׳Université de Montréal, Montreal, QC, Canada;5. Montreal Neurological Institute, McGill University, Montreal, QC, Canada;1. MRC Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, & Neuroscience (IoPPN), King’s College London, 16 De Crespigny Park, Denmark Hill, London, SE5 8AF, UK;2. Division of Psychiatry and Applied Psychology, Institute of Mental Health, University of Nottingham, Jubilee Campus, Triumph Road, Nottingham, NG7 2TU, UK;1. Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino, Università di Firenze, Viale Pieraccini 6, 50139, Firenze, Italy;2. S.O.D. Psichiatria, Azienda Ospedaliero-Universitaria Careggi, 50139 Firenze, Italy;3. Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Università di Palermo, Corso Tukory 129, 90134, Palermo, Italy;4. Maria Beatrice Passani Dipartimento di Scienze della Salute Università di Firenze, Viale Pieraccini 6, 50139, Firenze, Italy;1. Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA;2. Department of Internal Medicine, University of Utah, Salt Lake City, UT;1. Royal Agricultural University, Stroud Road, Cirencester, Gloucestershire GL7 6JS, United Kingdom;2. Aberystwyth University, Penglais, Aberystwyth, Ceredigion SY23 3DA, United Kingdom;3. School of Health Sciences and Social Work, University of Portsmouth, James Watson West Building, 2 King Richard 1 st Road, Portsmouth, Hampshire PO1 2FR, United Kingdom;1. The Biorobotics Institute, Sant’Anna School of Advanced Studies, Viale Rinaldo Piaggio 34, 56025 Pontedera (PI), Italy;2. Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain;3. Department of Physics, University of Pisa, Largo Bruno Pontecorvo 3, 56127 Pisa, Italy |
| |
| Abstract: | Central dopaminergic (DA) function in children was assessed by monitoring plasma-free homovanillic acid (pHVA) levels after brief (18 hour) administration with debrisoquin sulfate, a peripherally active antihypertensive agent that blocks peripheral, but not central, HVA production. Brief debrisoquin administration resulted in marked reductions in pHVA in each of six patients studied. In five of the six patients, post-debrisoquin pHVA levels remained relatively stable over the six-hour period of observation. No significant cardiovascular or behavioral side effects of debrisoquin were observed. The brief debrisoquin administration method appears to be a safe, simple, and potentially valid peripheral technique for evaluating aspects of central dopaminergic function in children with neuropsychiatric disorders. Additional work is needed to further establish this method's validity and reliability. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
